H. Bengü ÇOBANOĞLU, Yasemin TİMURKAYNAK, Mehmet İMAMOĞLU

Clinical management of tinnitus

Aim: Tinnitus is defined as the perception of sound or sounds without any external audible source. Unknown ethiopathological mechanisms with lack of standardized protocol in symptom evaluation, causes difficulties in clinical management. Therefore, we aimed to evaluate the efficacy of magnesium, misoprostol and lidocaine treatments in patients with tinnitus.Material and Methods: The 58 tinnitus cases, were evaluated retrospectively. A total number of 40 patients who were able to comply with the scheduled therapy were received two staged therapy. As first line therapy, 20 patients with sensorineural hearing loss and acoustic trauma history were received oral magnesium, while remaining 20 cases without hearing loss were received oral misoprostol. Tinnitus handicap inventory (THI) was applied to all patients before and one month after the therapy. As second line therapy, 1.5mg/kg intravenous lidocaine was administered to the patients who had ineffective treatment results according to the THI.Results: The 40 patients included in this study were 10 female (25%), and 30 male (75%) and the mean age of all patients was 41,47 years. In both magnesium and misoprostol group, the mean scores of post-treatment THI were significantly lower than pre-treatment THI scores (p-values=0,001 and 0,007, respectively). No statistically significant difference was found between pre - and post treatment scores of the THI in lidocaine group.Conclusion: In present study, it was demonstrated that magnesium treatment is effective on tinnitus cases with acoustic trauma and misoprostol is effective on normal hearing tinnitus group, whereas intravenous lidocaine treatment was not found to be effective in tinnitus.

PDF

___

1. Zarenoe R, Bohn Erik PT, An T, et al. Multidisciplinary group information for patients with tinnitus: an open trial. Hearing, Balance and Communication 2018;19:1-6.
2. Hu J, Xu J, Streelman M, et al. The Correlation of the Tinnitus Handicap Inventory with Depression and Anxiety in Veterans with Tinnitus. Int J Otolaryngol.2015;2015:689375.
3. Bogo R, Farah A, Karl PT, et al.Prevalence, incidence proportion, and heritability for tinnitus: a longitudinal twin study. Ear Hear 2017;38:292-300.
4. Pawełczyk M, Rajkowska E, Kotyło P, Dudarewicz A, Camp G, Śliwińska-Kowalska M. Analysis of inner ear potassium recycling genes as potential factors associated with tinnitus. Int J Occup Med Environ Health 2012;25:356-64.
5. Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. Otolaryngol Head Neck Surg. 2014;151:1-40.
6. Li T, Liu J, Li L, et al. Observation of Lidocainesuppressed Decrease of Magnesium in Salicylateinduced Tinnitus with an Online Electrochemical System. Electroanalysis 2018;30:1011-6.
7. Martz E, Jelleberg C, Dougherty DD, et al. Tinnitus, Depression, Anxiety, and Suicide: A Retrospective Analysis. Arch Phys Med Rehabil 2016;97:19.
8. Watts EJ, Fackrell K, Smith S, et al. Why Is Tinnitus a Problem? A Qualitative Analysis of Problems Reported by Tinnitus Patients. Trends Hear 2018;22:2331216518812250.
9. Jastreboff PJ. 25 years of tinnitus retraining therapy. HNO 2015;63:307-11.
10. Zenner HP, Delb W, Kröner-Herwig B, et al. A multidisciplinary systematic review of the treatment for chronic idiopathic tinnitus. Eur Arch Otorhinolaryngol 2017;274:2079-91.
11. Swain SK, Nayak S, Ravan JR, Sahu MC. Tinnitus and its current treatment–Still an enigma in medicine. J Formosan Med 2016;115:139-44.
12. Elgoyhen AB, Langguth B, De Ridder D, et al. Tinnitus: perspectives from human neuroimaging. Nat Rev Neurosci 2015;16:632.
13. Newman CW, Jacobson GP, Spitzer JB. Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg 1996;122:143-8.
14. Aksoy S, Firat Y, Alpar R. The Tinnitus Handicap Inventory: a study of validity and reliability. Int Tinnitus J 2007;13:94.
15. Langguth B, Elgoyhen AB, Cederroth CR. Therapeutic Approaches to the Treatment of Tinnitus. nnu Rev Pharmacol Toxicol 2018;25:3-23.
16. Bhatt JM, Lin HW, Bhattacharyya N. Prevalence, severity, exposures, and treatment patterns of tinnitus in the United States. JAMA Otolaryngology–Head & Neck Surgery 2016;142:959-65.
17. Axel PT, An A, Ringdahl A. Tinnitus: A study of its prevalence and Characteristics. Br J Audiol 1989;23:53-62.
18. Langguth B, Kleinjung T, Fischer B, et al. Tinnitus severity, depression, and the big five personality traits. Prog Brain Res 2007;166:221-5.
19. Lim JJ, Lu PK, Koh DS, et al.Impact of tinnitus as measured by the Tinnitus Handicap Inventory among tinnitus sufferers in Singapore. Singapore Med J 2010;51:551.
20. Karabulut H, Acar B. Tinnitus Hastalarında Tinnitus Engelilik Anketi İle Odyometrik Bulguların Arasındaki İlişki. Anatol J Clın Investig 2010;4:22-7.
21. Langguth B, Elgoyhen AB. Current pharmacological treatments for tinnitus. Expert Opin Pharmacother 2012;13:2495-509.
22. Konig O, Winter E, Fuchs J, et al.Protective effect of magnesium and MK 801 on hypoxia-induced hair cell loss in new-born rat cochlea. Magnes Res 2003;16: 98-105.
23. Uluyol S, Kılıçaslan S, Yağız Ö. Relationship between serum magnesium level and subjective tinnitus. Kulak Burun Bogaz Ihtis Derg 2016;26:225-7.
24. Cevette MJ, Barrs DM, Patel A, et al. Phase 2 study examining magnesium-dependent tinnitus. Int Tinnitus J 2011;16:168-73.
25. Patterson MB, Balough BJ. Review of pharmacological therapy for tinnitus. Int Tinnitus J 2006;12:149.
26. Briner W, House J, O’Leary M. Synthetic prostaglandin E1 misoprostol as a treatment for tinnitus. Arch Otolaryngol Head Neck Surg 1993;119:652-4.
27. Yılmaz İ, Çakmak Ö, Özlüoğlu LN. Diabet ve hipertansiyonu olan tinnituslu hastalarda misoprostol kullanımı, Otoskop 2001; 3:115-26.
28. Yılmaz İ, Akkuzu B, Çakmak Ö, ve ark. Misoprostol in the treatment of tinnitus: a double-blind study. Otolaryngol Head Neck Surg 2004;130:604-10.
29. Kallio H, Niskanen ML, Havia M, et al. IV ropivacaine compared with lidocaine for the treatment of tinnitus. Br J Anaesth 2008;101:261-5.